Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Melanoma Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SILV/PMEL drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SILV/PMEL ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SILV Products |
| Gene Delivery | SILV/PMEL Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SILV Products |
| Benchmark Ab | Anti-SILV/PMEL (Sequence of Tebentafusp-related gp100 binders) Recombinant positive control. |
View SILV Products |
| Validator | SILV/PMEL siRNA Set For knockdown verification. |
View SILV Products |
| Related Target A | CD3E Key component in T-cell engager bispecifics (e.g., Tebentafusp gp100 x CD3). |
View CD3E Products |
| Related Target B | TYR (Tyrosinase) Melanocyte lineage antigen co-expressed with PMEL, ideal for combination or multi-target screening. |
View TYR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Specificity validation against lineage homologs | Human/Mouse/Cyno ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily and lineage counter-screening | Homolog panel proteins (TYR, TYRP1, MLANA) strictly verified by mass spectrometry. |
| Lack of positive control benchmarks | Recombinant Clinical Benchmark Antibodies (Biosimilars) available. |
| Off-target and false positive determination | Sequence-verified siRNA sets included for target-specific knockdown validation. |
Live SILV/PMEL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SILV/PMEL (gp100) therapeutics is intensifying, with major players shifting focus from traditional peptide vaccines to TCR-bispecifics and TCR-T cell therapies. As first-generation therapies like Tebentafusp (Kimmtrak) establish clinical proof-of-concept in uveal melanoma, the next wave of R&D is targeting TCR-mimic (TCRm) antibodies and solid tumor-targeted CAR-Ts that can recognize low-density HLA-presented gp100 epitopes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-Bispecific | Immunocore | Uveal Melanoma, Cutaneous Melanoma | pMHC Binding Affinity Validation (Need high-purity CD3E and monomeric antigens) |
| TCR-T / CAR-T | Adaptimmune, Academic Institutions | Advanced Melanoma | Target density quantification & stable cell line construction (Need Lentivirus for expression) |
| TCR-mimic mAb | Eureka Therapeutics, BioNTech | Solid Tumors | Epitope specificity & cross-reactivity screening (Need recombinant target proteins) |